All the news Showing 10 of 39 articles from: Treatment for previous non-responders & relapsersGet an RSS feed of these articles Show All news infohep newsEditors' picks from other sources Re-treatment of hepatitis C is highly effective after the first combination fails Keith Alcorn / 24 June 2022 Two combinations proved highly effective in curing hepatitis C in people who had experienced the failure of a previous combination containing an NS5A inhibitor, studies in Europe and New Zealand show. The findings, ... Three-drug regimen plus ribavirin cures the hardest-to-treat hepatitis C patients Keith Alcorn / 08 December 2021 People who have experienced failure of multiple courses of direct-acting antiviral treatment can be cured of hepatitis C with a combination of three direct-acting antivirals plus ribavirin, a review of heavily treatment-experienced patients ... US regulator approves Gilead's Vosevi combo pill for hepatitis C retreatment Liz Highleyman / 19 July 2017 On 18 July the US Food and Drug Administration (FDA) approved Gilead Sciences' Vosevi, a new once-daily combination pill containing sofosbuvir, velpatasvir, and voxilaprevir. Vosevi was approved as "salvage therapy" ... EASL issues new hepatitis C treatment recommendations for all genotypes Liz Highleyman / 26 September 2016 The European Association for the Study of the Liver (EASL) released its latest recommendations on treatment of hepatitis C at a special meeting last Thursday in Paris. The updated guidelines now include highly ... High HCV cure rate demonstrated for people retreated after failure of short course direct-acting antiviral therapy Liz Highleyman / 09 December 2015 People with hepatitis C who did not achieve sustained virological response with a prior short course of direct-acting antiviral (DAA) therapy had a high likelihood of being cured if treated again with sofosbuvir/ledipasvir ... Treatment intensification with sofosbuvir permits cure after failure of previous HCV treatment Keith Alcorn / 17 November 2015 Re-treating with an interferon-free regimen that previously failed to cure hepatitis C can result in success if treatment is intensified with the addition of sofosbuvir, two studies presented this week at the ... Sofosbuvir-based therapy effective for hepatitis C patients with decompensated cirrhosis Liz Highleyman / 06 May 2015 Interferon-free regimens containing sofosbuvir (Sovaldi) plus simeprevir (Olysio) cured about three-quarters of people with genotype 1 chronic hepatitis C with advanced cirrhosis and MELD scores >10 in the real-world HCV-TARGET study, researchers reported ... When a short course of sofosbuvir/ledipasvir fails, some people can be cured of hepatitis C with a double treatment duration Liz Highleyman / 05 May 2015 More than 70% of people with chronic genotype 1 hepatitis C who did not achieve a sustained virological response when treated with sofosbuvir/ledipasvir (Harvoni) for 8 or 12 weeks were cured with a ... Grazoprevir/elbasvir highly effective in treatment-experienced and HIV-coinfected hepatitis C patients Keith Alcorn / 25 April 2015 The combination of grazoprevir and elbasvir without ribavirin is highly effective in curing hepatitis C infection in 12 weeks in some groups of treatment-experienced patients and in people with HIV co-infection, and a ... Merck HCV combination effective after failure of first generation of direct-acting antivirals Keith Alcorn / 24 April 2015 A 12-week course of treatment with two direct-acting antivirals in development by Merck plus ribavirin cured 95% of people with hepatitis C who had experienced failure of a previous treatment combination containing a ... ← First123...4Next → Other pages in this section Latest news All the news Hepatitis A Hepatitis B Hepatitis C Hepatitis D Hepatitis E Coronavirus NAFLD Treatment for hepatocellular carcinoma Transmission, epidemiology and prevention Health services, policy and advocacy Social issues Conference news Email bulletin archive